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Using reaction time and
co-contraction to differentiate
acquired (secondary) from
functional ‘ﬁxed’ dystonia
Emphasis has been placed on the import-
ance of making a positive diagnosis in
functional (psychogenic) movement disor-
ders. It has been suggested that ‘laboratory-
supported criteria’ should be developed
where electrophysiological and other
tests can improve the level of certainty of
diagnosis.1 Such criteria have been sug-
gested for functional myoclonus1 and func-
tional tremor.2 We report a preliminary
study aimed at developing similar criteria
for patients with ‘ﬁxed’ dystonia (FD),3 a
common presentation of functional
dystonia.4
We performed surface electromyogra-
phy (EMG) to assess the motor unit
action potentials (MUAPs) in agonists and
antagonists of the affected limb in patients
with either functional FD (n=9, etable 1A),
documented or clinically established follow-
ing Fahn and Williams4 criteria, or acquired
(n=9, etable 1B) dystonia (AD) due to brain
lesions affecting an upper or lower limb.
The inclusion criteria for the AD cases were
the presence of brain lesions consistent with
the clinical pattern of the dystonia.
We recorded EMG at rest and during a
reaction time (RT) task where patients
were asked to attempt to move in the
opposite direction to the habitual limb
posture after an auditory ‘go’ cue. Most
participants had been receiving chronic
treatment with botulinum toxin injec-
tions; however, they had not received the
treatment for more than 3 months before
the study. Dramatic immediate response
to botulinum toxin is reported in similar
patients. Participants were seated in a
comfortable armchair. EMG was moni-
tored with Ag/AgCl surface electrodes
positioned on the agonist and antagonist
muscles studied. The EMG activity was
recorded at rest for 5 s, and then each
trial included two auditory cues (100 ms,
rise–fall time 20/20 ms, frequency 1000–
5000 kHz). The initial sound was the
warning stimulus and the second was the
‘go’ stimulus. The patients were asked to
perform an isometric muscle contraction
of muscles opposing the ﬁxed posture as
quickly as possible (contraction task) and
to relax as soon as possible after the end
of the go signal. The tasks involved
ﬂexion or extension of the wrist or
plantar ﬂexion or dorsiﬂexion depending
on the muscles involved in the habitual
posture. The go signal was delivered at
ﬁve different intervals (2.5, 3, 3.5, 4 and
4.5 s) from the warning signal. The order
of ﬁve states was pseudorandomised. The
intertrial interval was greater than 15 s to
avoid the effect of fatigue during the task
and to allow for relaxation before each
trial. For each patient, 70 trials were
recorded. During recording, data were
averaged and stored in a computer for
off-line analysis. Data were analysed
ofﬂine using Signal software (Cambridge
Electronic Design, UK). The recordings were
DC corrected and rectiﬁed. The RTand dur-
ation of MUAPs were measured manually
for each trial. The amplitude of MUAPs was
automatically computed. SPSS Statistics soft-
ware (V.21.0.0) was used for the statistical
analysis. Kolmogorov-Smirnoff test was used
to measure the normality of the data distri-
bution. When not normally distributed, the
data were subjected to a log10 transform-
ation. To compare the RT data between the
two groups, we conducted an independent t
test. Whereas to study the level of
co-contraction in the two different diagno-
ses, we conducted a repeated measures
multiway analysis of variance (ANOVA) on
the data using the following factors:
CONDITION (rest vs contractions),
MUSCLE (agonist vs antagonist) and
GROUP (FD vs AD). Post hoc tests were
conducted with Bonferroni corrections for
multiple comparisons. p Values less than
0.05 were considered to be signiﬁcant.
Patients with AD had longer RT com-
pared with patients with FD (238.9±50.3
vs 173.3±35.1 ms; t=−3.21, df=16;
p=0.005; ﬁgure 1A). Although this
measure separates the groups of patients,
the scatter plot of the RTs for each patient
indicates an overlap in the RT of the two
groups (ﬁgure 1B). Repeated measures
ANOVA (rmANOVA) of the ratio between
EMG amplitude of agonist and the
EMG amplitude of the antagonist with
CONDITION (rest vs contraction) and
MUSCLE (agonist vs antagonist) as within-
subject factors and GROUP (FD vs SD) as
between-subject factor showed an effect of
MUSCLE (F1,22.8=1.11; p<0.001) and
Figure 1 Mean values of the
reaction times (RT) during the
contraction tasks in the agonist
muscles of patients with ﬁxed dystonia
and acquired dystonia. Statistical
signiﬁcance (unpaired t tests):
***p<0.01 (A). Scatter plots of RT for
each patient (B). Ratio amplitude of
electromyography (EMG) activity
between agonist and antagonist
muscles involving in the task at rest
and during voluntary movement
opposing to ﬁxed posture, statistical
signiﬁcance: *p<0.05 (C). Scatter plots
of EMG amplitude agonist/antagonist
ratio during contraction for each
patient (D).
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CONDITION (F1,82.42=12.07; p<0.001).
In addition, there was a signiﬁcant
MUSCLE×CONDITION interaction
(F1,38.53=1.67; p<0.001) and MUSCLE×
DIAGNOSIS interaction (F1,18.74=0.91;
p=0.001). There was no signiﬁcant effect of
diagnosis (F1,0.56=0.25; p>0.05). Post hoc
tests with Bonferroni correction showed no
differences in EMG activity between FD and
AD groups at rest.
To explore the difference in the level of
co-contraction in the two groups, we per-
formed a post hoc rmANOVA of EMG
amplitude ratio between agonist and
antagonist during the two conditions (at
rest and during contraction). There was a
signiﬁcant effect of the CONDITION
(F1,14.90=0.65; p=0.002) and a signiﬁ-
cant effect of the DIAGNOSIS (F1,4.8=
0.92; p=0.04). Post hoc analysis showed
that the EMG amplitude was higher
during contraction in both groups and the
ratio was higher in patients with FD than
in those with AD; that is, patients with
FD have less co-contraction than patients
with AD (ﬁgure 1C). Despite this group
difference, the scatter plot of the ratio
between agonist/antagonist EMG activities
for each patient showed overlap in the
values of the two groups (ﬁgure 1D).
Reliable clinical diagnosis of functional
FD is known to be challenging. We report
an EMG study to explore RT and
co-contraction as possible measures in this
regard in functional dystonia compared
with a form of organic dystonia that
causes ﬁxed postures.
We found a long RT in patients with
AD, similar to previous results in primary
dystonia.5 Patients with FD showed RT
values similar to those reported in histor-
ical cohorts of healthy patients.5
Furthermore, patients with FD had lower
levels of co-contraction during a voluntary
movement compared to those with AD.
Notably, the individual data on RT and
co-contraction show clear overlap between
the two groups. Thus, even if these two
parameters can be useful to differentiate at
a group level, they are not suitable in this
form as diagnostic criteria. Moreover, we
did not ﬁnd a pattern of response that was
abnormal in a different manner to AD (eg,
failure to activate the muscles requested),
which would have allowed a more positive
differentiation of FD from AD.
Although the ﬁndings of our study
show promise in better classifying this
common disorder, we appreciate the limi-
tation of lack of a healthy control group
in the investigation. These data therefore
represent an initial attempt to provide
laboratory criteria for FD, but there is
clearly still an unmet need for a positive
laboratory test to support clinical diagno-
sis in FD.
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